Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: A sub analysis of the Treat to Target ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2007-12

AUTHORS

Ulrich Kintscher, Peter Bramlage, W Dieter Paar, Martin Thoenes, Thomas Unger

ABSTRACT

OBJECTIVES: The metabolic syndrome is a cluster of cardiovascular risk factors leading to an increased risk for the subsequent development of diabetes and cardiovascular morbidity and mortality. Blocking the renin-angiotensin system has been shown to prevent cardiovascular disease and delay the onset of diabetes. Irbesartan is an angiotensin receptor blocker (ARB) which has been shown to possess peroxisome proliferator-activated receptor gamma (PPARgamma) activating properties, and to have a favorable metabolic profile. Current discussion is whether the addition of small doses of hydrochlorothiazide changes this profile. Therefore the efficacy, safety and metabolic profile of Irbesartan either as monotherapy or in combination therapy was assessed in patients with the metabolic syndrome in a large observational cohort in primary care. RESEARCH DESIGN AND METHODS: Multicenter, prospective, two-armed, post authorization study over 9 months in 14,200 patients with uncontrolled hypertension with and without the metabolic syndrome (doctors' diagnosis based on the Adult Treatment Panel III criteria 2001). Blood pressure was measured sphygmomanometrically and cardiovascular risk factors making up the criteria for the metabolic syndrome were assessed. MAIN OUTCOME MEASURES: Systolic (SBP) and diastolic (DBP) blood pressure reduction, response, and normalization (systolic and diastolic), changes in fasting glucose, waist circumference (abdominal obesity), serum triglycerides and HDL cholesterol as well as the proportion of patients fulfilling the criteria for the metabolic syndrome. Number and nature of adverse events (AEs). RESULTS: After 9 month the use of Irbesartan in monotherapy resulted in a significant reduction of blood pressure (SBP: -26.3 +/- 10.1 mmHg/DBP-13.0 +/- 6.6 mmHg, both p < 0.0001) in patients with the metabolic syndrome. This was accompanied by a reduction in cardiovascular risk factors: HDL cholesterol (+3.6 +/- 7.2 mg/dl in men, +3.8 +/- 6.5 mg/dl in women, both p < 0.0001), serum triglycerides (-28.6 +/- 52.1 mg/dl, p < 0.0001), fasting blood glucose (-8.4 +/- 25.1 mg/dl, p < 0.0001) and waist circumference (-2.4 +/- 11.9 cm in men, -1.2 +/- 14.2 in women, both p < 0.0001) were significantly improved. Irbesartan combination therapy (12.5 mg HCTZ) in patients with the metabolic syndrome: blood pressure reduction (SBP: -27.5 +/- 10.1 mmHg/DBP: -14.1 +/- 6.6 mmHg, both p < 0.0001), improvement in HDL cholesterol (+4.0 +/- 6.8 mg/dl in men, +3.4 +/- 6.8 in women, both p < 0.0001), triglycerides (-34.1 +/- 52.6 mg/dl, p < 0.0001), fasting blood glucose (-10.0 +/- 24.7, p < 0.0001) and waist circumference (-3.2 +/- 12.7 cm in men, -1.7 +/- 14.4 in women, both p < 0.0001). Tolerability was excellent: only 0.6% of patients experienced an AE. CONCLUSION: There was a significant improvement in blood pressure and metabolic risk factors as a result of Irbesartan treatment. There was no evidence of a difference between monotherapy and combination therapy with regard to the cardiovascular risk profile. More... »

PAGES

12

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/1475-2840-6-12

DOI

http://dx.doi.org/10.1186/1475-2840-6-12

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1040398603

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/17407587


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Abdominal Fat", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Angiotensin II Type 1 Receptor Blockers", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antihypertensive Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biphenyl Compounds", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Blood Glucose", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Blood Pressure", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cardiovascular Diseases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cholesterol, HDL", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cohort Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Therapy, Combination", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fasting", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hydrochlorothiazide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypertension", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Metabolic Syndrome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tetrazoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Triglycerides", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Charit\u00e9", 
          "id": "https://www.grid.ac/institutes/grid.6363.0", 
          "name": [
            "Center for Cardiovascular Research (CCR), Institute of Pharmacology, Charit\u00e9, Berlin, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kintscher", 
        "givenName": "Ulrich", 
        "id": "sg:person.0636477725.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0636477725.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "TU Dresden", 
          "id": "https://www.grid.ac/institutes/grid.4488.0", 
          "name": [
            "Institute for Clinical Pharmacology, Medical Faculty Carl-Gustav Carus, Technical University Dresden, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bramlage", 
        "givenName": "Peter", 
        "id": "sg:person.01304431360.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304431360.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sanofi (Germany)", 
          "id": "https://www.grid.ac/institutes/grid.420214.1", 
          "name": [
            "Sanofi-Aventis Deutschland GmbH, Medical Affairs CardioVascularThrombosis, Berlin, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Paar", 
        "givenName": "W Dieter", 
        "id": "sg:person.01220266165.99", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01220266165.99"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sanofi (France)", 
          "id": "https://www.grid.ac/institutes/grid.417924.d", 
          "name": [
            "Sanofi-Aventis, Medical Affairs, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Thoenes", 
        "givenName": "Martin", 
        "id": "sg:person.01205715672.60", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01205715672.60"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Charit\u00e9", 
          "id": "https://www.grid.ac/institutes/grid.6363.0", 
          "name": [
            "Center for Cardiovascular Research (CCR), Institute of Pharmacology, Charit\u00e9, Berlin, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Unger", 
        "givenName": "Thomas", 
        "id": "sg:person.0752125516.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752125516.35"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s001250051268", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001153018", 
          "https://doi.org/10.1007/s001250051268"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s001250051268", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001153018", 
          "https://doi.org/10.1007/s001250051268"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00004872-200406000-00024", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002454474"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00004872-200406000-00024", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002454474"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00004872-199917020-00001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003918995"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00004872-199917020-00001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003918995"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00004872-199917020-00001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003918995"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00044011-200020010-00001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004560003", 
          "https://doi.org/10.2165/00044011-200020010-00001"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00044011-200020010-00001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004560003", 
          "https://doi.org/10.2165/00044011-200020010-00001"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.hyp.0000123072.34629.57", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005277791"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.hyp.0000123072.34629.57", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005277791"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diacare.24.4.683", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005367642"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.hyp.0000168046.19884.6a", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007193277"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.hyp.0000168046.19884.6a", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007193277"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.hyp.0000168046.19884.6a", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007193277"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1524-6175.2004.04720.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008782891"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diacare.26.3.575", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009237000"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.288.21.2709", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009474275"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.cir.0000080897.52664.94", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010001455"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003495-199200441-00013", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010937770", 
          "https://doi.org/10.2165/00003495-199200441-00013"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1262-3636(07)70067-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014292627"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.288.23.2981", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016077891"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3317/jraas.2003.026", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018201506"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3317/jraas.2003.026", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018201506"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1475-2840-4-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018238203", 
          "https://doi.org/10.1186/1475-2840-4-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00038-004-3063-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022661411", 
          "https://doi.org/10.1007/s00038-004-3063-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.cir.0000127955.36250.65", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029448060"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/01.hjh.0000133732.24501.9e", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030294418"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/01.hjh.0000133732.24501.9e", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030294418"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/circulationaha.105.169404", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030755840"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.cir.0000141736.76561.78", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032387441"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1146/annurev.nutr.23.011702.073212", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033009996"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.hyp.0000215181.60228.f7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038043341"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.hyp.0000215181.60228.f7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038043341"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1146/annurev.nutr.22.010402.102808", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038789731"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1373/clinchem.2006.067397", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038911332"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1185/030079904x3861", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040600148"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1073/pnas.93.22.12490", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041835884"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/hy1101.092970", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042478946"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(02)08089-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044050224"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00044011-199918060-00004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047815854", 
          "https://doi.org/10.2165/00044011-199918060-00004"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/01.hjh.0000242405.68461.84", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051813961"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/01.hjh.0000242405.68461.84", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051813961"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1046/j.1440-1681.2003.03911.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052144102"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm200006223422507", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053038763"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.febslet.2004.09.027", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1054735137"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1210/jcem.87.2.7980", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064324894"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/circ.106.25.3143", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1075204771"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077945134", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2007-12", 
    "datePublishedReg": "2007-12-01", 
    "description": "OBJECTIVES: The metabolic syndrome is a cluster of cardiovascular risk factors leading to an increased risk for the subsequent development of diabetes and cardiovascular morbidity and mortality. Blocking the renin-angiotensin system has been shown to prevent cardiovascular disease and delay the onset of diabetes. Irbesartan is an angiotensin receptor blocker (ARB) which has been shown to possess peroxisome proliferator-activated receptor gamma (PPARgamma) activating properties, and to have a favorable metabolic profile. Current discussion is whether the addition of small doses of hydrochlorothiazide changes this profile. Therefore the efficacy, safety and metabolic profile of Irbesartan either as monotherapy or in combination therapy was assessed in patients with the metabolic syndrome in a large observational cohort in primary care.\nRESEARCH DESIGN AND METHODS: Multicenter, prospective, two-armed, post authorization study over 9 months in 14,200 patients with uncontrolled hypertension with and without the metabolic syndrome (doctors' diagnosis based on the Adult Treatment Panel III criteria 2001). Blood pressure was measured sphygmomanometrically and cardiovascular risk factors making up the criteria for the metabolic syndrome were assessed.\nMAIN OUTCOME MEASURES: Systolic (SBP) and diastolic (DBP) blood pressure reduction, response, and normalization (systolic and diastolic), changes in fasting glucose, waist circumference (abdominal obesity), serum triglycerides and HDL cholesterol as well as the proportion of patients fulfilling the criteria for the metabolic syndrome. Number and nature of adverse events (AEs).\nRESULTS: After 9 month the use of Irbesartan in monotherapy resulted in a significant reduction of blood pressure (SBP: -26.3 +/- 10.1 mmHg/DBP-13.0 +/- 6.6 mmHg, both p < 0.0001) in patients with the metabolic syndrome. This was accompanied by a reduction in cardiovascular risk factors: HDL cholesterol (+3.6 +/- 7.2 mg/dl in men, +3.8 +/- 6.5 mg/dl in women, both p < 0.0001), serum triglycerides (-28.6 +/- 52.1 mg/dl, p < 0.0001), fasting blood glucose (-8.4 +/- 25.1 mg/dl, p < 0.0001) and waist circumference (-2.4 +/- 11.9 cm in men, -1.2 +/- 14.2 in women, both p < 0.0001) were significantly improved. Irbesartan combination therapy (12.5 mg HCTZ) in patients with the metabolic syndrome: blood pressure reduction (SBP: -27.5 +/- 10.1 mmHg/DBP: -14.1 +/- 6.6 mmHg, both p < 0.0001), improvement in HDL cholesterol (+4.0 +/- 6.8 mg/dl in men, +3.4 +/- 6.8 in women, both p < 0.0001), triglycerides (-34.1 +/- 52.6 mg/dl, p < 0.0001), fasting blood glucose (-10.0 +/- 24.7, p < 0.0001) and waist circumference (-3.2 +/- 12.7 cm in men, -1.7 +/- 14.4 in women, both p < 0.0001). Tolerability was excellent: only 0.6% of patients experienced an AE.\nCONCLUSION: There was a significant improvement in blood pressure and metabolic risk factors as a result of Irbesartan treatment. There was no evidence of a difference between monotherapy and combination therapy with regard to the cardiovascular risk profile.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/1475-2840-6-12", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1031021", 
        "issn": [
          "1475-2840"
        ], 
        "name": "Cardiovascular Diabetology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "6"
      }
    ], 
    "name": "Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: A sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients", 
    "pagination": "12", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "c070b3291c4375024196f75880e81cee1b40e443baeb119fe36879fbf8ec1a8d"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "17407587"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101147637"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/1475-2840-6-12"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1040398603"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/1475-2840-6-12", 
      "https://app.dimensions.ai/details/publication/pub.1040398603"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T20:47", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8684_00000514.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1186%2F1475-2840-6-12"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/1475-2840-6-12'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/1475-2840-6-12'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/1475-2840-6-12'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/1475-2840-6-12'


 

This table displays all metadata directly associated to this object as RDF triples.

313 TRIPLES      21 PREDICATES      89 URIs      44 LITERALS      32 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/1475-2840-6-12 schema:about N033c8a2f44c84cceadc5a5c2672ae991
2 N0cdf1006650e44438f985ef0931633c9
3 N0d131035374749b39440440827f91ca7
4 N1217240d194e453eb0a5393d619a816a
5 N1231b8cab9dd4ed2858155e05bb22d98
6 N19861cd8b682424988328f1e22b38ae4
7 N21893481e1bf4cd5b99952237450f421
8 N262ced9390e2440696ce5231d25413c0
9 N4070dae68acb4bb4a594b882ea8513ff
10 N51c3307d8243456db27b9ecc6e0f70a5
11 N5d9d5fe2c6d34fcc8794a3649819a04d
12 N79f6b32fe3a249c089dab8997d5a011c
13 N8a5088359e5d434bb093c4897253d4d0
14 N99fa390bb1a94a668772ae237b39cfdf
15 N9fbde87873154c4cbdf7104de10c8e45
16 Na2dc5aac962d4d589ee4eb40163dfec6
17 Na4f656d67f21477cb61c937409d5965c
18 Naa3a95498bff400bbee1c2dd9bf4a872
19 Nc3438ff5f00047198dc9dd07cda1e5c5
20 Ne15682fee9fc484f9e6ed75be68d9b83
21 Ne92e8aaef9d5494e94c17ef3a2b54756
22 Nf06db9522e6748afa5300693b9141e07
23 Nf4ba346f10d144ab83e3cccbebc3fe9c
24 anzsrc-for:11
25 anzsrc-for:1102
26 schema:author N0fbd36e325b048d78c8b3d6a5f0d7de8
27 schema:citation sg:pub.10.1007/s00038-004-3063-5
28 sg:pub.10.1007/s001250051268
29 sg:pub.10.1186/1475-2840-4-6
30 sg:pub.10.2165/00003495-199200441-00013
31 sg:pub.10.2165/00044011-199918060-00004
32 sg:pub.10.2165/00044011-200020010-00001
33 https://app.dimensions.ai/details/publication/pub.1077945134
34 https://doi.org/10.1001/jama.288.21.2709
35 https://doi.org/10.1001/jama.288.23.2981
36 https://doi.org/10.1016/j.febslet.2004.09.027
37 https://doi.org/10.1016/s0140-6736(02)08089-3
38 https://doi.org/10.1016/s1262-3636(07)70067-8
39 https://doi.org/10.1046/j.1440-1681.2003.03911.x
40 https://doi.org/10.1056/nejm200006223422507
41 https://doi.org/10.1073/pnas.93.22.12490
42 https://doi.org/10.1097/00004872-199917020-00001
43 https://doi.org/10.1097/00004872-200406000-00024
44 https://doi.org/10.1097/01.hjh.0000133732.24501.9e
45 https://doi.org/10.1097/01.hjh.0000242405.68461.84
46 https://doi.org/10.1111/j.1524-6175.2004.04720.x
47 https://doi.org/10.1146/annurev.nutr.22.010402.102808
48 https://doi.org/10.1146/annurev.nutr.23.011702.073212
49 https://doi.org/10.1161/01.cir.0000080897.52664.94
50 https://doi.org/10.1161/01.cir.0000127955.36250.65
51 https://doi.org/10.1161/01.cir.0000141736.76561.78
52 https://doi.org/10.1161/01.hyp.0000123072.34629.57
53 https://doi.org/10.1161/01.hyp.0000168046.19884.6a
54 https://doi.org/10.1161/01.hyp.0000215181.60228.f7
55 https://doi.org/10.1161/circ.106.25.3143
56 https://doi.org/10.1161/circulationaha.105.169404
57 https://doi.org/10.1161/hy1101.092970
58 https://doi.org/10.1185/030079904x3861
59 https://doi.org/10.1210/jcem.87.2.7980
60 https://doi.org/10.1373/clinchem.2006.067397
61 https://doi.org/10.2337/diacare.24.4.683
62 https://doi.org/10.2337/diacare.26.3.575
63 https://doi.org/10.3317/jraas.2003.026
64 schema:datePublished 2007-12
65 schema:datePublishedReg 2007-12-01
66 schema:description OBJECTIVES: The metabolic syndrome is a cluster of cardiovascular risk factors leading to an increased risk for the subsequent development of diabetes and cardiovascular morbidity and mortality. Blocking the renin-angiotensin system has been shown to prevent cardiovascular disease and delay the onset of diabetes. Irbesartan is an angiotensin receptor blocker (ARB) which has been shown to possess peroxisome proliferator-activated receptor gamma (PPARgamma) activating properties, and to have a favorable metabolic profile. Current discussion is whether the addition of small doses of hydrochlorothiazide changes this profile. Therefore the efficacy, safety and metabolic profile of Irbesartan either as monotherapy or in combination therapy was assessed in patients with the metabolic syndrome in a large observational cohort in primary care. RESEARCH DESIGN AND METHODS: Multicenter, prospective, two-armed, post authorization study over 9 months in 14,200 patients with uncontrolled hypertension with and without the metabolic syndrome (doctors' diagnosis based on the Adult Treatment Panel III criteria 2001). Blood pressure was measured sphygmomanometrically and cardiovascular risk factors making up the criteria for the metabolic syndrome were assessed. MAIN OUTCOME MEASURES: Systolic (SBP) and diastolic (DBP) blood pressure reduction, response, and normalization (systolic and diastolic), changes in fasting glucose, waist circumference (abdominal obesity), serum triglycerides and HDL cholesterol as well as the proportion of patients fulfilling the criteria for the metabolic syndrome. Number and nature of adverse events (AEs). RESULTS: After 9 month the use of Irbesartan in monotherapy resulted in a significant reduction of blood pressure (SBP: -26.3 +/- 10.1 mmHg/DBP-13.0 +/- 6.6 mmHg, both p < 0.0001) in patients with the metabolic syndrome. This was accompanied by a reduction in cardiovascular risk factors: HDL cholesterol (+3.6 +/- 7.2 mg/dl in men, +3.8 +/- 6.5 mg/dl in women, both p < 0.0001), serum triglycerides (-28.6 +/- 52.1 mg/dl, p < 0.0001), fasting blood glucose (-8.4 +/- 25.1 mg/dl, p < 0.0001) and waist circumference (-2.4 +/- 11.9 cm in men, -1.2 +/- 14.2 in women, both p < 0.0001) were significantly improved. Irbesartan combination therapy (12.5 mg HCTZ) in patients with the metabolic syndrome: blood pressure reduction (SBP: -27.5 +/- 10.1 mmHg/DBP: -14.1 +/- 6.6 mmHg, both p < 0.0001), improvement in HDL cholesterol (+4.0 +/- 6.8 mg/dl in men, +3.4 +/- 6.8 in women, both p < 0.0001), triglycerides (-34.1 +/- 52.6 mg/dl, p < 0.0001), fasting blood glucose (-10.0 +/- 24.7, p < 0.0001) and waist circumference (-3.2 +/- 12.7 cm in men, -1.7 +/- 14.4 in women, both p < 0.0001). Tolerability was excellent: only 0.6% of patients experienced an AE. CONCLUSION: There was a significant improvement in blood pressure and metabolic risk factors as a result of Irbesartan treatment. There was no evidence of a difference between monotherapy and combination therapy with regard to the cardiovascular risk profile.
67 schema:genre research_article
68 schema:inLanguage en
69 schema:isAccessibleForFree true
70 schema:isPartOf N6f5aa967d01b4f34badc10fd1b1a0080
71 Nfc715270083441aca54c5e652d641617
72 sg:journal.1031021
73 schema:name Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: A sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients
74 schema:pagination 12
75 schema:productId N143a873fa17746d7b2b854ef80667a36
76 N6ed9c519d114404d984d198fcf06418c
77 N72ba421894f749b099b84a0a43a315c6
78 Na5eb1f46a1a24eb3a77f19783833bcf6
79 Nd75532b6af68440bbbd02bc22db17dad
80 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040398603
81 https://doi.org/10.1186/1475-2840-6-12
82 schema:sdDatePublished 2019-04-10T20:47
83 schema:sdLicense https://scigraph.springernature.com/explorer/license/
84 schema:sdPublisher N9967bef951104f44897cdb43c49fd316
85 schema:url http://link.springer.com/10.1186%2F1475-2840-6-12
86 sgo:license sg:explorer/license/
87 sgo:sdDataset articles
88 rdf:type schema:ScholarlyArticle
89 N033c8a2f44c84cceadc5a5c2672ae991 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Fasting
91 rdf:type schema:DefinedTerm
92 N0cdf1006650e44438f985ef0931633c9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
93 schema:name Risk Factors
94 rdf:type schema:DefinedTerm
95 N0d131035374749b39440440827f91ca7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
96 schema:name Cohort Studies
97 rdf:type schema:DefinedTerm
98 N0fbd36e325b048d78c8b3d6a5f0d7de8 rdf:first sg:person.0636477725.27
99 rdf:rest N9fedd1926bb6415fa178f478f7c195dc
100 N1217240d194e453eb0a5393d619a816a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Hydrochlorothiazide
102 rdf:type schema:DefinedTerm
103 N1231b8cab9dd4ed2858155e05bb22d98 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Female
105 rdf:type schema:DefinedTerm
106 N143a873fa17746d7b2b854ef80667a36 schema:name dimensions_id
107 schema:value pub.1040398603
108 rdf:type schema:PropertyValue
109 N19861cd8b682424988328f1e22b38ae4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Blood Glucose
111 rdf:type schema:DefinedTerm
112 N21893481e1bf4cd5b99952237450f421 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Metabolic Syndrome
114 rdf:type schema:DefinedTerm
115 N262ced9390e2440696ce5231d25413c0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Cholesterol, HDL
117 rdf:type schema:DefinedTerm
118 N4070dae68acb4bb4a594b882ea8513ff schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Middle Aged
120 rdf:type schema:DefinedTerm
121 N51c3307d8243456db27b9ecc6e0f70a5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Triglycerides
123 rdf:type schema:DefinedTerm
124 N5d9d5fe2c6d34fcc8794a3649819a04d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Abdominal Fat
126 rdf:type schema:DefinedTerm
127 N6ed9c519d114404d984d198fcf06418c schema:name doi
128 schema:value 10.1186/1475-2840-6-12
129 rdf:type schema:PropertyValue
130 N6f5aa967d01b4f34badc10fd1b1a0080 schema:issueNumber 1
131 rdf:type schema:PublicationIssue
132 N72ba421894f749b099b84a0a43a315c6 schema:name pubmed_id
133 schema:value 17407587
134 rdf:type schema:PropertyValue
135 N79f6b32fe3a249c089dab8997d5a011c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Tetrazoles
137 rdf:type schema:DefinedTerm
138 N8a5088359e5d434bb093c4897253d4d0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Aged
140 rdf:type schema:DefinedTerm
141 N9967bef951104f44897cdb43c49fd316 schema:name Springer Nature - SN SciGraph project
142 rdf:type schema:Organization
143 N99fa390bb1a94a668772ae237b39cfdf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Male
145 rdf:type schema:DefinedTerm
146 N9f31372441c64955866c5356f4da62ee rdf:first sg:person.0752125516.35
147 rdf:rest rdf:nil
148 N9fbde87873154c4cbdf7104de10c8e45 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Hypertension
150 rdf:type schema:DefinedTerm
151 N9fedd1926bb6415fa178f478f7c195dc rdf:first sg:person.01304431360.27
152 rdf:rest Nb9a4e951bb1a4d8699268fdb3f71ea96
153 Na2dc5aac962d4d589ee4eb40163dfec6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Biphenyl Compounds
155 rdf:type schema:DefinedTerm
156 Na4f656d67f21477cb61c937409d5965c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Angiotensin II Type 1 Receptor Blockers
158 rdf:type schema:DefinedTerm
159 Na5eb1f46a1a24eb3a77f19783833bcf6 schema:name readcube_id
160 schema:value c070b3291c4375024196f75880e81cee1b40e443baeb119fe36879fbf8ec1a8d
161 rdf:type schema:PropertyValue
162 Naa3a95498bff400bbee1c2dd9bf4a872 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Blood Pressure
164 rdf:type schema:DefinedTerm
165 Nb9a4e951bb1a4d8699268fdb3f71ea96 rdf:first sg:person.01220266165.99
166 rdf:rest Nfd75dd5672ce437fbab4016afcc1edc1
167 Nc3438ff5f00047198dc9dd07cda1e5c5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Cardiovascular Diseases
169 rdf:type schema:DefinedTerm
170 Nd75532b6af68440bbbd02bc22db17dad schema:name nlm_unique_id
171 schema:value 101147637
172 rdf:type schema:PropertyValue
173 Ne15682fee9fc484f9e6ed75be68d9b83 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Prospective Studies
175 rdf:type schema:DefinedTerm
176 Ne92e8aaef9d5494e94c17ef3a2b54756 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Antihypertensive Agents
178 rdf:type schema:DefinedTerm
179 Nf06db9522e6748afa5300693b9141e07 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Humans
181 rdf:type schema:DefinedTerm
182 Nf4ba346f10d144ab83e3cccbebc3fe9c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Drug Therapy, Combination
184 rdf:type schema:DefinedTerm
185 Nfc715270083441aca54c5e652d641617 schema:volumeNumber 6
186 rdf:type schema:PublicationVolume
187 Nfd75dd5672ce437fbab4016afcc1edc1 rdf:first sg:person.01205715672.60
188 rdf:rest N9f31372441c64955866c5356f4da62ee
189 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
190 schema:name Medical and Health Sciences
191 rdf:type schema:DefinedTerm
192 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
193 schema:name Cardiorespiratory Medicine and Haematology
194 rdf:type schema:DefinedTerm
195 sg:journal.1031021 schema:issn 1475-2840
196 schema:name Cardiovascular Diabetology
197 rdf:type schema:Periodical
198 sg:person.01205715672.60 schema:affiliation https://www.grid.ac/institutes/grid.417924.d
199 schema:familyName Thoenes
200 schema:givenName Martin
201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01205715672.60
202 rdf:type schema:Person
203 sg:person.01220266165.99 schema:affiliation https://www.grid.ac/institutes/grid.420214.1
204 schema:familyName Paar
205 schema:givenName W Dieter
206 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01220266165.99
207 rdf:type schema:Person
208 sg:person.01304431360.27 schema:affiliation https://www.grid.ac/institutes/grid.4488.0
209 schema:familyName Bramlage
210 schema:givenName Peter
211 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304431360.27
212 rdf:type schema:Person
213 sg:person.0636477725.27 schema:affiliation https://www.grid.ac/institutes/grid.6363.0
214 schema:familyName Kintscher
215 schema:givenName Ulrich
216 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0636477725.27
217 rdf:type schema:Person
218 sg:person.0752125516.35 schema:affiliation https://www.grid.ac/institutes/grid.6363.0
219 schema:familyName Unger
220 schema:givenName Thomas
221 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752125516.35
222 rdf:type schema:Person
223 sg:pub.10.1007/s00038-004-3063-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022661411
224 https://doi.org/10.1007/s00038-004-3063-5
225 rdf:type schema:CreativeWork
226 sg:pub.10.1007/s001250051268 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001153018
227 https://doi.org/10.1007/s001250051268
228 rdf:type schema:CreativeWork
229 sg:pub.10.1186/1475-2840-4-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018238203
230 https://doi.org/10.1186/1475-2840-4-6
231 rdf:type schema:CreativeWork
232 sg:pub.10.2165/00003495-199200441-00013 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010937770
233 https://doi.org/10.2165/00003495-199200441-00013
234 rdf:type schema:CreativeWork
235 sg:pub.10.2165/00044011-199918060-00004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047815854
236 https://doi.org/10.2165/00044011-199918060-00004
237 rdf:type schema:CreativeWork
238 sg:pub.10.2165/00044011-200020010-00001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004560003
239 https://doi.org/10.2165/00044011-200020010-00001
240 rdf:type schema:CreativeWork
241 https://app.dimensions.ai/details/publication/pub.1077945134 schema:CreativeWork
242 https://doi.org/10.1001/jama.288.21.2709 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009474275
243 rdf:type schema:CreativeWork
244 https://doi.org/10.1001/jama.288.23.2981 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016077891
245 rdf:type schema:CreativeWork
246 https://doi.org/10.1016/j.febslet.2004.09.027 schema:sameAs https://app.dimensions.ai/details/publication/pub.1054735137
247 rdf:type schema:CreativeWork
248 https://doi.org/10.1016/s0140-6736(02)08089-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044050224
249 rdf:type schema:CreativeWork
250 https://doi.org/10.1016/s1262-3636(07)70067-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014292627
251 rdf:type schema:CreativeWork
252 https://doi.org/10.1046/j.1440-1681.2003.03911.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1052144102
253 rdf:type schema:CreativeWork
254 https://doi.org/10.1056/nejm200006223422507 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053038763
255 rdf:type schema:CreativeWork
256 https://doi.org/10.1073/pnas.93.22.12490 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041835884
257 rdf:type schema:CreativeWork
258 https://doi.org/10.1097/00004872-199917020-00001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003918995
259 rdf:type schema:CreativeWork
260 https://doi.org/10.1097/00004872-200406000-00024 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002454474
261 rdf:type schema:CreativeWork
262 https://doi.org/10.1097/01.hjh.0000133732.24501.9e schema:sameAs https://app.dimensions.ai/details/publication/pub.1030294418
263 rdf:type schema:CreativeWork
264 https://doi.org/10.1097/01.hjh.0000242405.68461.84 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051813961
265 rdf:type schema:CreativeWork
266 https://doi.org/10.1111/j.1524-6175.2004.04720.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1008782891
267 rdf:type schema:CreativeWork
268 https://doi.org/10.1146/annurev.nutr.22.010402.102808 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038789731
269 rdf:type schema:CreativeWork
270 https://doi.org/10.1146/annurev.nutr.23.011702.073212 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033009996
271 rdf:type schema:CreativeWork
272 https://doi.org/10.1161/01.cir.0000080897.52664.94 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010001455
273 rdf:type schema:CreativeWork
274 https://doi.org/10.1161/01.cir.0000127955.36250.65 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029448060
275 rdf:type schema:CreativeWork
276 https://doi.org/10.1161/01.cir.0000141736.76561.78 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032387441
277 rdf:type schema:CreativeWork
278 https://doi.org/10.1161/01.hyp.0000123072.34629.57 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005277791
279 rdf:type schema:CreativeWork
280 https://doi.org/10.1161/01.hyp.0000168046.19884.6a schema:sameAs https://app.dimensions.ai/details/publication/pub.1007193277
281 rdf:type schema:CreativeWork
282 https://doi.org/10.1161/01.hyp.0000215181.60228.f7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038043341
283 rdf:type schema:CreativeWork
284 https://doi.org/10.1161/circ.106.25.3143 schema:sameAs https://app.dimensions.ai/details/publication/pub.1075204771
285 rdf:type schema:CreativeWork
286 https://doi.org/10.1161/circulationaha.105.169404 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030755840
287 rdf:type schema:CreativeWork
288 https://doi.org/10.1161/hy1101.092970 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042478946
289 rdf:type schema:CreativeWork
290 https://doi.org/10.1185/030079904x3861 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040600148
291 rdf:type schema:CreativeWork
292 https://doi.org/10.1210/jcem.87.2.7980 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064324894
293 rdf:type schema:CreativeWork
294 https://doi.org/10.1373/clinchem.2006.067397 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038911332
295 rdf:type schema:CreativeWork
296 https://doi.org/10.2337/diacare.24.4.683 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005367642
297 rdf:type schema:CreativeWork
298 https://doi.org/10.2337/diacare.26.3.575 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009237000
299 rdf:type schema:CreativeWork
300 https://doi.org/10.3317/jraas.2003.026 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018201506
301 rdf:type schema:CreativeWork
302 https://www.grid.ac/institutes/grid.417924.d schema:alternateName Sanofi (France)
303 schema:name Sanofi-Aventis, Medical Affairs, Paris, France
304 rdf:type schema:Organization
305 https://www.grid.ac/institutes/grid.420214.1 schema:alternateName Sanofi (Germany)
306 schema:name Sanofi-Aventis Deutschland GmbH, Medical Affairs CardioVascularThrombosis, Berlin, Germany
307 rdf:type schema:Organization
308 https://www.grid.ac/institutes/grid.4488.0 schema:alternateName TU Dresden
309 schema:name Institute for Clinical Pharmacology, Medical Faculty Carl-Gustav Carus, Technical University Dresden, Germany
310 rdf:type schema:Organization
311 https://www.grid.ac/institutes/grid.6363.0 schema:alternateName Charité
312 schema:name Center for Cardiovascular Research (CCR), Institute of Pharmacology, Charité, Berlin, Germany
313 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...